In a couple of large, phase-3, placebo-controlled trials (FIDELIO-DKD and FIGARO-DKD), finerenone reduced both the progression of chronic kidney disease (CKD) and cardiovascular events in patients with CKD associated with type 2 diabetes (T2D) already on blockers of the renin–angiotensin system [17,18]. This evidence concerns the gene REN and chronic kidney disease.